Titre:	Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia
Auteur(s):	Ramos, Doralina do Amaral Rabello Araujo, Antonio Roberto Lucena Silva, Juliana Carvalho Rocha Alves Eira, Vinícius Burnett Aboud Souza da Vasconcellos, Maria Catarina Cals de Oliveira, Fábio Morato de Rêgo, Eduardo Magalhães Araujo, Felipe Saldanha de Pittella-Silva, Fabio
metadata.dc.contributor.affiliation:	Universidade de Brasília, Faculdade de Ciências da Saúde, Laboratório de Patologia Molecular do Câncer
Assunto::	Leucemia linfocítica crônica (LLC) Histonas Metiltransferase Expressão gênica Citogenética
Date de publication:	2015
Editeur:	Elsevier
Référence bibliographique:	RABELLO, Doralina do Amaral et al. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells, Molecules, and Diseases, [S.l.], v. 54, n. 1, p. 97-102, 2015. DOI: https://doi.org/10.1016/j.bcmd.2014.07.013.
Abstract:	EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness.
DOI:	https://doi.org/10.1016/j.bcmd.2014.07.013
metadata.dc.relation.publisherversion:	https://www.sciencedirect.com/science/article/pii/S1079979614000928?via%3Dihub
Collection(s) :	Artigos publicados em periódicos e afins

Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.